FDA Approvals, Successful Product Launches, Upcoming Earnings Schedules and Quarterly Financial Results - Research Report on

 FDA Approvals, Successful Product Launches, Upcoming Earnings Schedules and
   Quarterly Financial Results - Research Report on Pfizer, Mettler-Toledo,
                    Arena, Wright Medical, and Ophthotech

PR Newswire

NEW YORK, November 7, 2013

NEW YORK, November 7, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Pfizer
Inc. (NYSE: PFE), Mettler-Toledo International Inc. (NYSE: MTD), Arena
Pharmaceuticals, Inc. (NASDAQ: ARNA), Wright Medical Group, Inc. (NASDAQ:
WMGI), and Ophthotech Corporation (NASDAQ: OPHT). Today's readers may access
these reports free of charge - including full price targets, industry analysis
and analyst ratings - via the links below.

Pfizer Inc. Research Report

On November 4, 2013, Pfizer Inc. (Pfizer) announced that the FDA has approved
a Prior Approval Supplement for EMBEDA (morphine sulfate and naltrexone
hydrochloride) Extended Release Capsules CII. The Company informed that the
Prior Approval Supplement included an update to the EMBEDA manufacturing
process, addressing the pre-specified stability requirement that led to the
voluntary recall of EMBEDA from the market in March 2011. Pfizer expects
product availability in Q2 2014. The Full Research Report on Pfizer Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/d702_PFE]

Mettler-Toledo International Inc. Research Report

On October 22, 2013, Mettler-Toledo Thornton, a division of Mettler-Toledo
International Inc., announced the launch of the Pure Water Optical Dissolved
Oxygen (ODO) Sensor. The Company informed that when paired with the Thornton
M800 transmitter, the ODO Sensor provides high accuracy, fast response, and
increased stability in demanding low ppb-level applications. Commenting on the
launch, Christie Martin, Global Product Manager of Mettler-Toledo Thornton
said, "The Pure Water Optical DO Sensor has a 33% faster response time over
competitive optical models and is six times faster than traditional
polarographic sensors, making it the fastest ODO measurement available on the
market today." The Full Research Report on Mettler-Toledo International Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/ac69_MTD]

Arena Pharmaceuticals, Inc. Research Report

On October 30, 2013, Arena Pharmaceuticals, Inc. (Arena) announced that it
will release its Q3 2013 financial results, as well as provide a corporate
update, on November 7, 2013, after the NASDAQ Global Select Market closes. On
the same day, the Company will host a conference call and webcast at 5:00 p.m.
ET / 2:00 p.m. PT. The Full Research Report on Arena Pharmaceuticals, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/6a95_ARNA]

Wright Medical Group, Inc. Research Report

On November 4, 2013, Wright Medical Group, Inc. (Wright Medical) reported its
Q3 2013 financial results. During the quarter, the Company's net sales
increased 13.3% YoY to $57.6 million. Q3 2013 net loss was $130.0 million, or
$2.80 per diluted share, compared with a net loss of $5.3 million, or $0.14
per diluted share, in Q3 2012. "Notably, we were able to accelerate our growth
rate in our U.S. foot and ankle business despite the ongoing transition
activities as a result of the MicroPort transaction," said Robert Palmisano,
President and CEO of Wright Medical. "We were pleased to see another quarter
of strong international growth with positive progress in market development in
several key countries. In addition, our recent agreement to acquire Biotech
International represents another important step in the transformation of our
business to a dedicated Extremities-Biologics company exclusively focused on
extending our leadership position in this fast growing and underpenetrated
market and is an important addition from which our international business can
continue to grow." The Full Research Report on Wright Medical Group, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

[http://www.analystscorner.com/r/full_research_report/1782_WMGI]

OphthotechCorporation Research Report

On October 30, 2013, Ophthotech Corporation (Ophthotech) announced that it
will release its Q3 2013 financial results on November 13, 2013, before the US
financial markets open. On the same day, the Company will host a conference
call at 8:30 a.m. ET to discuss the results, as well as to provide a corporate
update. The Full Research Report on Ophthotech Corporation - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

[http://www.analystscorner.com/r/full_research_report/91ff_OPHT]

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Media Contact: Joe Thomas, +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.